Therapeutic Strategy in Advanced Bronchioloalveolar Carcinoma

Intergroupe Francophone de Cancerologie Thoracique

Status and phase: Completed; Phase 2

Conditions: Adenocarcinoma, Bronchiolo-Alveolar

Treatments: Drug: erlotinib; Drug: paclitaxel + carboplatine

Study type: Interventional

Funder types: Other

Identifiers

NCT00384826

IFCT-0504

Details and patient eligibility

About

To evaluate among patients with untreated advanced ADC-CBA, impact on the disease control rate after 4 months treatment of an early therapeutic permutation with the first month in the absence of stabilization or objective answer.

Enrollment: 133 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• CBA histologically proven (or cytologically with pneumonic presentation) PS < 3 signed and written informed consent

Exclusion criteria

• visible tumoral lesion in bronchial fibroscopy

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

133 participants in 2 patient groups

1

Experimental group

Treatment:

Drug: erlotinib

2

Experimental group

Treatment:

Drug: paclitaxel + carboplatine